Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable.

Gatti M., Andreoni M., Pea F., Viale P. (2021). Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs. DRUG DESIGN, DEVELOPMENT AND THERAPY, 15, 3349-3378 [10.2147/DDDT.S313756].

Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs

Gatti M.;Pea F.;Viale P.
2021

Abstract

Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable.
2021
Gatti M., Andreoni M., Pea F., Viale P. (2021). Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: A careful appraisal beyond approved indications focusing on unmet clinical needs. DRUG DESIGN, DEVELOPMENT AND THERAPY, 15, 3349-3378 [10.2147/DDDT.S313756].
Gatti M.; Andreoni M.; Pea F.; Viale P.
File in questo prodotto:
File Dimensione Formato  
DDDT-313756-real-world-use-of-dalbavancin-in-the-era-of-empowerment-of-o.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 2.44 MB
Formato Adobe PDF
2.44 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/837193
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 33
social impact